Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NSCLC, metastatic 1

2191 - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations (NEJ009)


19 Oct 2018


Poster Discussion session - NSCLC, metastatic 1


Cytotoxic Therapy;  Targeted Therapy

Tumour Site


Masahiro Seike


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


M. Seike1, A. Inoue2, S. Sugawara3, S. Morita4, Y. Hosomi5, S. Ikeda6, K. Watanabe7, K. Takahashi8, Y. Fujita9, T. Harada10, K. Minato11, K. Takamura12, K. Kobayashi13, T. Nukiwa14

Author affiliations

  • 1 Department Of Pulmonary Medicine And Oncology, Nippon Medical School, 11138603 - Tokyo/JP
  • 2 Department Of Palliative Medicine, Tohoku University School of Medicine, Miyagi/JP
  • 3 Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP
  • 4 Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine 54 Kawahara-cho,Shogoin,Sakyo-ku, Kyoto/JP
  • 5 Department Of Thoracic Oncology & Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 6 Division Of Respiratory Medicine, Cardiovascular & Respiratory Center, 2360051 - Yokohama/JP
  • 7 Department Of Respiratory Medicine, Miyagi Cancer Center, Natori/JP
  • 8 Department Of Respiratory Medicine, Juntendo University Graduate School of Medicine, 1138431 - Tokyo/JP
  • 9 Respiratory Medicine, Asahikawa Medical Center, 708644 - Asahikawa/JP
  • 10 Department Of Pulmonary Medicine, JCHO Hokkaido Hospital, 062-8618 - Sapporo/JP
  • 11 Department Of Pulmonary Medicine, Gunma Prefectural Cancer Center, 373-8550 - Ota/JP
  • 12 First Department Of Mediine, Obihiro Kosei General Hospital, Obihiro/JP
  • 13 Department Of Pulmonary Medicine, Saitama Medical University Internatl Medical Centre, 350-1298 - Saitama/JP
  • 14 Professor Emeritus, Tohoku University, Sendai/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2191


Although EGFR-TKI alone has been a standard first-line treatment for pts with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP. NEJ009, an open-label, randomized phase III study, was conducted to evaluate the superiority of GCP vs G in progression-free survival (PFS), PFS2, and overall survival (OS).


Pts with newly diagnosed stage III/IV/recurrent NSCLC harboring EGFR activating mutations (exon 19 deletion or exon 21 L858R) were randomized 1:1 to G 250 mg PO QD or GCP (G 250mg PO QD combined with carboplatin AUC 5 + pemetrexed 500mg/m2, every 3 weeks). The primary endpoints consisting of PFS, PFS2, and OS were sequentially analyzed according to a preplanned gate-keeping method. Secondary endpoints included objective response rate, safety, and quality of life.


From Oct 2011 to Sep 215, 345 pts were enrolled and 342 pts (G 172, GCP 170) were evaluated. Baseline characteristics fairly well balanced between the arms. GCP demonstrated significantly better PFS compared to G as below. Although there was no difference in PFS2 between the arms, additional OS analysis (G 101 events vs GCP 83 events) revealed that median survival time of GCP was much longer than that of G (52.2 months vs 38.8 months, HR: 0.695, p = 0.013). Details of post-protocol treatments in both arms will be presented at the meeting.


NEJ009 was the first phase III study which evaluated the efficacy of a combination of EGFR-TKI and platinum doublet chemotherapy in untreated advanced NSCLC pts with EGFR mutations. Although GCP regimen failed to demonstrate its superiority in PFS2, it increased long survivors.Table: 1382PD

ITT populationGCP (N = 169)G (N = 172)
Median (months)Median (months)HR
95%CI:18.0, 24.295%CI:9.0,13.495%CI:0.390, 0.623
P < 0.001
95%CI:18.0,24.295%CI:17.9,24.995%CI: 0.708,1.122
P = 0.806
OS (additional analysis) (P = 0.013)

Clinical trial identification

Legal entity responsible for the study

North East Japan Study Group (NEJ).


Has not received any funding.

Editorial Acknowledgement


M. Seike: Lecture fees: AstraZeneca, Eli Lilly, Taiho Pharmaceutical. A. Inoue: Lecture fees: AstraZeneca, Eli Lilly, Boehringer Ingelheim, MSD, Chugai, Pfizer. S. Sugawara: Lecture fees: AstraZeneca, Chugai Pharma, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, Eli Lilly and Company, Novartis, Kyowa Hakko Kirin, Bristol-Myers Squibb, Ono Pharmaceutical, MSD K.K. S. Morita: Lecture fees: AstraZeneca, Eli Lilly. Y. Hosomi: Lecture fees: AstraZeneca, Taiho Pharmaceutical, Lilly, Chugai Phama, Ono Taiho Pharmaceutical, Bristol-Myers Squibb Japan, MSD. K. Takahashi: Lecture fees and research funding: AstraZeneca, Eli Lilly. Y. Fujita: Lecture fees: Chugai, Ono, Eli Lilly; Research funding: Taiho, Chugai, Eli Lilly, Pfizer Japan. K. Minato: Research funding: Taiho, Bristol-Myers Squibb, Quintiles. K. Kobayashi: Lecture fees: AstraZeneca, Chugai, Ono, Eli Lilly; Consulting or advisory role fee: AstraZeneca. T. Nukiwa: Lecture fees: Asahi-Kasei, Nippon Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.